Dr Wallace J Hayasaka, MD | |
915 Highland Blvd, Bozeman, MT 59715-6902 | |
(602) 262-8900 | |
(602) 262-4132 |
Full Name | Dr Wallace J Hayasaka |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 28 Years |
Location | 915 Highland Blvd, Bozeman, Montana |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1477538155 | NPI | - | NPPES |
26353580 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 57767 (Montana) | Primary |
207L00000X | Anesthesiology | 52953 (Arizona) | Secondary |
207L00000X | Anesthesiology | 38727 (Colorado) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Billings Clinic | Billings, MT | Hospital |
Bozeman Health Deaconess Hospital | Bozeman, MT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Gallatin Valley Anesthesia Associates Pc | 1456372523 | 32 |
News Archive
When treating the diabetes patient, doctors discussed how a "one size fits all" approach to testing is not enough to reveal an individual's risk for cardiovascular disease Saturday at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress.
Two new studies published this week in Biological Psychiatry shed light on the propensity for habit formation in obsessive-compulsive disorder (OCD). These studies suggest that a tendency to develop habits, i.e., the compulsive component of the disorder, may be a core feature of the disorder rather than a consequence of irrational beliefs.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
The results of a study presented today at the European League Against Rheumatism Annual Congress showed that tiny particles made of a biodegradable polymer (BNPs - biodegradable polymer nanoparticles) have the potential to enable early detection and efficient long-term treatment of rheumatoid arthritis (RA), with minimal side effects.
› Verified 1 days ago
Entity Name | Livingston Healthcare |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1245222306 PECOS PAC ID: 5991613598 Enrollment ID: O20031122000111 |
News Archive
When treating the diabetes patient, doctors discussed how a "one size fits all" approach to testing is not enough to reveal an individual's risk for cardiovascular disease Saturday at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress.
Two new studies published this week in Biological Psychiatry shed light on the propensity for habit formation in obsessive-compulsive disorder (OCD). These studies suggest that a tendency to develop habits, i.e., the compulsive component of the disorder, may be a core feature of the disorder rather than a consequence of irrational beliefs.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
The results of a study presented today at the European League Against Rheumatism Annual Congress showed that tiny particles made of a biodegradable polymer (BNPs - biodegradable polymer nanoparticles) have the potential to enable early detection and efficient long-term treatment of rheumatoid arthritis (RA), with minimal side effects.
› Verified 1 days ago
Entity Name | Gallatin Valley Anesthesia Associates Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1336165182 PECOS PAC ID: 1456372523 Enrollment ID: O20051216000229 |
News Archive
When treating the diabetes patient, doctors discussed how a "one size fits all" approach to testing is not enough to reveal an individual's risk for cardiovascular disease Saturday at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress.
Two new studies published this week in Biological Psychiatry shed light on the propensity for habit formation in obsessive-compulsive disorder (OCD). These studies suggest that a tendency to develop habits, i.e., the compulsive component of the disorder, may be a core feature of the disorder rather than a consequence of irrational beliefs.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
The results of a study presented today at the European League Against Rheumatism Annual Congress showed that tiny particles made of a biodegradable polymer (BNPs - biodegradable polymer nanoparticles) have the potential to enable early detection and efficient long-term treatment of rheumatoid arthritis (RA), with minimal side effects.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Wallace J Hayasaka, MD Po Box 84891, Seattle, WA 98124-6191 Ph: (406) 414-5000 | Dr Wallace J Hayasaka, MD 915 Highland Blvd, Bozeman, MT 59715-6902 Ph: (602) 262-8900 |
News Archive
When treating the diabetes patient, doctors discussed how a "one size fits all" approach to testing is not enough to reveal an individual's risk for cardiovascular disease Saturday at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress.
Two new studies published this week in Biological Psychiatry shed light on the propensity for habit formation in obsessive-compulsive disorder (OCD). These studies suggest that a tendency to develop habits, i.e., the compulsive component of the disorder, may be a core feature of the disorder rather than a consequence of irrational beliefs.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
The results of a study presented today at the European League Against Rheumatism Annual Congress showed that tiny particles made of a biodegradable polymer (BNPs - biodegradable polymer nanoparticles) have the potential to enable early detection and efficient long-term treatment of rheumatoid arthritis (RA), with minimal side effects.
› Verified 1 days ago
David Joly, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 931 Highland Blvd, Suite 3103, Bozeman, MT 59715 Phone: 406-599-9561 | |
Dr. Jeffrey Thomas Bolka, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 925 Highland Blvd, Bozeman, MT 59715 Phone: 406-414-5000 | |
Ms. Fiona Margaret Buckley, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Bozeman Deaconess Hospital, 915 Highland Blvd, Bozeman, MT 59715 Phone: 406-585-5000 | |
Philip C Cory, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 15075 Dell Road, Bozeman, MT 59715 Phone: 406-587-3523 | |
Lawrence A Alvarado Iii, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 925 Highland Blvd, Bozeman, MT 59715 Phone: 406-599-9561 | |
Erik R Bodtker, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 915 Highland Blvd, Bozeman, MT 59715 Phone: 800-461-3981 Fax: 801-733-5872 | |
Kevin Wayne Bozarth, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 915 Highland Blvd, Bozeman, MT 59715 Phone: 800-461-3981 Fax: 801-733-5872 |